Live
Audio Only
This trials will eventually include 350 minors who will get vaccinated with two doses of Sovereign 02 and one dose of Sovereign Plus.
On Monday, Cuba's Finlay Institute of Vaccines (IFV) began clinical trials of the Sovereign 02 COVID-19 vaccine in 25 children aged 3 to 11 years.
RELATED:
The IFV scientists stated the results of their research revealed that this vaccine had no adverse side effects in adolescents. Therefore, they included younger children in the group of volunteers who participate in pediatric clinical trials.
IFV director Yury Valdes explained this pediatric clinical trials will eventually include 350 minors, who will get vaccinated with two doses of Sovereign 02 and one dose of Sovereign Plus. The study does not include the application of placebos.
He also pointed out that this vaccination scheme was previously applied in the adult population with an efficacy of 62 percent.
Cuban candidate vaccines against Covid-19 Soberana 2 and Abdala are already being produced in #Cuba���� on a large scale. It is admirable to see how a small island like Cuba, blockaded by the United States, could be able to immunize most of its population by the end of 2021. pic.twitter.com/ZcJtzdLTrK
— El canario amarillo (@elcanarioamari1) February 26, 2021
Phase one of Sovereign pediatric clinical trial will take place at Juan Marquez Pediatric Hospital in Havana, while its phase two will be conducted at the primary care level, which involves several community polyclinics.
Although COVID-19 is usually mild or asymptomatic in pediatric ages, health authorities have pointed out that vaccinating children is essential to reach herd immunity and limit the disease severity.
Sovereign 02 vaccine fuses an antigen with a carrier coronavirus molecule to enhance its stability and efficacy. This vaccine only require between 8 and 2°C of refrigeration, which is a great advantage to countries of low resources.
Despite an intensified US blockade, #Cuba provides the world with two COVID-19 vaccines.
— teleSUR English (@telesurenglish) June 22, 2021
Soberana 02, with 62% efficacy after two doses—likely to rise after the Soberana Plus trial results are known.
Abdala, with 92.28% efficacy after three doses—the third highest worldwide. pic.twitter.com/xwT7jV7mMf
Newsletter
